Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Lava Therapeutics B-V stock | $7.13

Learn how to easily invest in Lava Therapeutics B-V stock.

Lava Therapeutics B.V is a biotechnology business based in the US. Lava Therapeutics B-V shares (LVTX) are listed on the NASDAQ and all prices are listed in US Dollars. Lava Therapeutics B-V employs 28 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Lava Therapeutics B-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LVTX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Lava Therapeutics B-V stock price (NASDAQ: LVTX)

Use our graph to track the performance of LVTX stocks over time.

Lava Therapeutics B-V shares at a glance

Information last updated 2021-10-10.
Latest market close$7.13
52-week range$5.50 - $17.20
50-day moving average $6.29
200-day moving average $9.73
Wall St. target price$23.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-5.05

Buy Lava Therapeutics B-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Lava Therapeutics B-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lava Therapeutics B-V price performance over time

Historical closes compared with the close of $7.13 from 2021-10-15

1 week (2021-10-08) 0.28%
1 month (2021-09-17) 16.69%
3 months (2021-07-16) -29.78%
6 months (2021-04-16) -52.47%
1 year (2020-10-14) N/A
2 years (2019-10-14) N/A
3 years (2018-10-14) N/A
5 years (2016-10-14) N/A

Lava Therapeutics B-V financials

Revenue TTM $4.4 million
Gross profit TTM $-10,453,000
Return on assets TTM -65.22%
Return on equity TTM -237.94%
Profit margin 0%
Book value $4.48
Market capitalisation $183.3 million

TTM: trailing 12 months

Shorting Lava Therapeutics B-V shares

There are currently 73,673 Lava Therapeutics B-V shares held short by investors – that's known as Lava Therapeutics B-V's "short interest". This figure is 18.1% up from 62,396 last month.

There are a few different ways that this level of interest in shorting Lava Therapeutics B-V shares can be evaluated.

Lava Therapeutics B-V's "short interest ratio" (SIR)

Lava Therapeutics B-V's "short interest ratio" (SIR) is the quantity of Lava Therapeutics B-V shares currently shorted divided by the average quantity of Lava Therapeutics B-V shares traded daily (recently around 31085.654008439). Lava Therapeutics B-V's SIR currently stands at 2.37. In other words for every 100,000 Lava Therapeutics B-V shares traded daily on the market, roughly 2370 shares are currently held short.

To gain some more context, you can compare Lava Therapeutics B-V's short interest ratio against those of similar companies.

However Lava Therapeutics B-V's short interest can also be evaluated against the total number of Lava Therapeutics B-V shares, or, against the total number of tradable Lava Therapeutics B-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Lava Therapeutics B-V's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Lava Therapeutics B-V shares in existence, roughly 0 shares are currently held short) or 0.0097% of the tradable shares (for every 100,000 tradable Lava Therapeutics B-V shares, roughly 10 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Lava Therapeutics B-V.

Find out more about how you can short Lava Therapeutics B-V stock.

Lava Therapeutics B-V share dividends

We're not expecting Lava Therapeutics B-V to pay a dividend over the next 12 months.

Lava Therapeutics B-V overview

Lava Therapeutics B. V. , a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B. V.

Frequently asked questions

What percentage of Lava Therapeutics B-V is owned by insiders or institutions?
Currently 31.559% of Lava Therapeutics B-V shares are held by insiders and 62.525% by institutions.
How many people work for Lava Therapeutics B-V?
Latest data suggests 28 work at Lava Therapeutics B-V.
When does the fiscal year end for Lava Therapeutics B-V?
Lava Therapeutics B-V's fiscal year ends in December.
Where is Lava Therapeutics B-V based?
Lava Therapeutics B-V's address is: Yalelaan 60, Utrecht, Netherlands, 3584 CM
What is Lava Therapeutics B-V's ISIN number?
Lava Therapeutics B-V's international securities identification number is: NL0015000AG6

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site